<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579539</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-120312</org_study_id>
    <nct_id>NCT01579539</nct_id>
  </id_info>
  <brief_title>The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy</brief_title>
  <official_title>The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid-associated ophthalmopathy (TAO), also called Graves' ophthalmopathy or thyroid eye&#xD;
      disease, is a common orbital disease in adults. Patients with TAO, especially in its active&#xD;
      phase, often complain about symptoms of ocular surface discomfort, including excess tearing,&#xD;
      gritty sensation, increased sensitivity to light and foreign-body sensation, which are&#xD;
      similar to inflammatory ocular surface disorders such as dry-eye syndrome (DES). Incomplete&#xD;
      blink, increased proptosis and greater palpebral fissure width in TAO accelerates tear&#xD;
      evaporation, which increases the tear fluid's osmolarity, and results in ocular surface&#xD;
      damage. The administration of intravenous glucocorticoids can be an effective treatment for&#xD;
      TAO.&#xD;
&#xD;
      The rationale of the present study is to assess the effect of intravenously administered&#xD;
      glucocorticoids on the signs of DES in patients with TAO with new methods such as measurement&#xD;
      of tear film thickness, tear film osmolarity and scattering of the tear film and well&#xD;
      established methods for assessment of the severity of DES. Additionally, impression cytology&#xD;
      and determination of tear cytokines/chemokines will be performed to obtain information about&#xD;
      inflammatory processes on the ocular surface.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2013</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">May 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear film thickness as measured with OCT</measure>
    <time_frame>13 weeks</time_frame>
    <description>Measurements of tear film thickness with OCT will be performed 7 or less days before start of treatment, 6 weeks after start of treatment and 12 weeks after start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Break up time (BUT)</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear film osmolarity</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of exophthalmia</measure>
    <time_frame>13 weeks</time_frame>
    <description>Hertel exophthalmometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palpebral fissure width</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSI (Objective Scattering Index)</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear cytokines/chemokines</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impression cytology</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staining of the cornea with fluorescein</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer I test</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective symptoms of dry eye syndrome</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Thyroid-associated Ophthalmopathy</condition>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate to severe thyroid-associated ophthalmopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>40mg i.v. infusion once a week for 12 weeks</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged over 18 years&#xD;
&#xD;
          -  Active thyroid associated ophthalmopathy with clinical activity score (CAS) of each&#xD;
             eye more than 3 or recently experienced worsening of proptosis, lid retraction, or&#xD;
             ocular motility disturbance.&#xD;
&#xD;
          -  Normal ophthalmic findings except symptoms associated with TAO&#xD;
&#xD;
          -  Scheduled for treatment with systemic glucocorticoids according to the kahaly-scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic inactive TAO&#xD;
&#xD;
          -  Previous treatment with oral or intravenous glucocorticoids 3 months preceding the&#xD;
             study&#xD;
&#xD;
          -  Participation in a clinical trial in the 3 weeks before the screening visit&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Presence or history of a severe medical condition that will interfere with the study&#xD;
             aim as judged by the clinical investigator&#xD;
&#xD;
          -  Wearing of contact lenses&#xD;
&#xD;
          -  Intake of dietary supplements in the 3 months preceding the study&#xD;
&#xD;
          -  Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except&#xD;
             topical lubricants&#xD;
&#xD;
          -  Ocular infection&#xD;
&#xD;
          -  Ocular surgery in the 3 months preceding the study&#xD;
&#xD;
          -  Sj√∂gren's syndrome&#xD;
&#xD;
          -  Stevens-Johnson syndrome&#xD;
&#xD;
          -  Pregnancy, planned pregnancy or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2012</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Ass. Prof. PD. Dr.</investigator_title>
  </responsible_party>
  <keyword>Methylprednisolone</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>Tear Film</keyword>
  <keyword>Thyroid-associated ophthalmopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

